LABD Dividend: Yield, Schedule, and What to Expect

Short answer

LABD's approximate ~2.4% (variable; inverse and leveraged funds make irregular distributions) yield (as of early 2026) makes it a growth-first, low-yield fund. It tracks -3x daily S&P Biotech Select Industry and passes through the dividends of its holdings, typically quarterly, minus a 1.07% (gross; about 0.95% net of acquired fund fees) expense ratio. If income is your goal, look to dedicated dividend funds for more; LABD is built for total return, not yield. If total return is the goal, the yield matters less than cost and what it holds. Yield is a recent snapshot, not a promise; verify the current figure with Direxion.

How does the LABD dividend work?

LABD holds the companies in -3x daily S&P Biotech Select Industry, collects the dividends they pay, and distributes them to shareholders (usually quarterly), net of its 1.07% (gross; about 0.95% net of acquired fund fees) fee. The yield you see is the trailing distributions divided by price, so it drifts as both change.

Direxion Daily S&P Biotech Bear 3X Shares (LABD) is a geared inverse exchange-traded fund that seeks daily investment results, before fees and expenses, equal to 300% of the inverse (-3x) of the daily performance of the S&P Biotechnology Select Industry Index. The fund uses swaps, futures, and short positions rather than holding a portfolio of stocks, so its disclosed holdings are derivative and cash instruments rather than individual companies. The S&P Biotechnology Select Industry Index is an equal-weighted basket of US biotechnology firms, a sector already known for sharp, news-driven swings around clinical trials, FDA decisions, and earnings. Applying -3x leverage to that base magnifies both gains and losses. Critically, LABD targets its -3x exposure on a single-day basis and rebalances daily. Over any holding period longer than one day, the compounding of daily returns means LABD's performance can diverge substantially from -3x the index's cumulative return, and in choppy or sideways markets this compounding works against holders, eroding value even if biotech is roughly flat. LABD carries a gross expense ratio around 1.07% (net near 0.95%), well above plain index funds, which adds a further long-term drag. It is designed for sophisticated traders seeking to profit from or hedge against short-term declines in biotech, with positions actively monitored and typically held for days, not months. Its bull counterpart is LABU (Direxion Daily S&P Biotech Bull 3X Shares), which seeks +3x the same index.

How does LABD's dividend yield compare?

Approximate yield: ~2.4% (variable; inverse and leveraged funds make irregular distributions) (early 2026).
What drives it: the payout of the underlying -3x daily S&P Biotech Select Industry holdings.
Fee drag: the 1.07% (gross; about 0.95% net of acquired fund fees) expense ratio is deducted before you receive distributions.
For more income: dedicated dividend or income ETFs target higher yield, with their own trade-offs.

If income is your goal, compare LABD against dividend-focused funds. See the best dividend ETFs roundup, or analyze how LABD's income fits your real portfolio in Walnut.

The bottom line on the LABD dividend

The bottom line: at an approximate ~2.4% (variable; inverse and leveraged funds make irregular distributions) yield, LABD is a growth-first, low-yield fund. If income is your goal, dedicated dividend funds pay more; LABD is the wrong tool for yield and the right one for total-return -3x daily S&P Biotech Select Industry exposure. If total return is the goal, the yield matters less than cost and what it holds. Treat the figure as a moving snapshot, not a fixed rate, and verify the current yield with Direxion.

Build a portfolio around LABD with Walnut

Use LABD as your core holding, then let Walnut's AI propose thematic satellites: AI infrastructure, dividend growth, clean energy, whatever you believe in. Connect your broker, build the basket in conversation, track it as one unit.

Create a free Walnut account

FAQ

What is LABD's dividend yield?

Approximately ~2.4% (variable; inverse and leveraged funds make irregular distributions) as of early 2026. Yield moves with price and distributions, so treat it as a recent snapshot and verify the current figure on Direxion's fund page.

How often does LABD pay a dividend?

Most US equity ETFs like LABD distribute dividends quarterly, passing through the dividends their underlying holdings pay. Confirm the exact schedule and ex-dividend dates with Direxion.

Where does LABD's dividend come from?

LABD tracks -3x daily S&P Biotech Select Industry and holds names such as . The fund collects the dividends those companies pay and passes them to you, minus the 1.07% (gross; about 0.95% net of acquired fund fees) expense ratio.

Can I reinvest LABD dividends?

Yes. Most brokers let you turn on automatic dividend reinvestment (a DRIP) so LABD distributions buy more shares automatically. This compounds over time but still counts as taxable income in a taxable account.

Is LABD a good choice for dividend income?

Walnut is informational, not investment advice. LABD yields roughly ~2.4% (variable; inverse and leveraged funds make irregular distributions), which is on the higher side for an equity ETF. Dedicated dividend ETFs target higher yield; broad-market funds prioritize total return over yield. Match the choice to whether you want income now or growth.

Are LABD dividends qualified?

Many dividends from a US large-cap equity ETF like LABD are qualified (taxed at lower long-term rates) if holding-period rules are met, but some portion can be ordinary. Tax treatment depends on your situation; confirm with a tax professional and Direxion's tax documents.

Walnut is informational, not investment advice. Dividend yields and schedules are approximate, stamped to early 2026, and change; verify current figures with Direxion or your broker.